Fulgent Genetics Inc (FLGT) FinancialsFLGTFulgent Genetics Inc

Fulgent Genetics, Inc. (FLGT) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Insurance, accounting for 51.8% of total sales, equivalent to $44.23M. Other significant revenue streams include Institutional and Patient. Understanding this composition is critical for investors evaluating how FLGT navigates market cycles within the Healthcare Facilities & Services industry.

Evaluating the bottom line, Fulgent Genetics, Inc. maintains a gross margin of 27.02%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -39.70%, while the net margin is -34.80%. These profitability ratios, combined with a Return on Equity (ROE) of -7.97%, provide a clear picture of how effectively FLGT converts its operational activities into shareholder value.

In the context of the broader market, FLGT competes directly with industry leaders such as SRTA and DNA. With a market capitalization of $539.57M, it holds a significant position in the sector. When comparing efficiency, FLGT's gross margin of 27.02% stands against SRTA's 11.84% and DNA's 91.47%. Such benchmarking helps identify whether Fulgent Genetics, Inc. is trading at a premium or discount relative to its financial performance.

Fulgent Genetics has shown a decline in profitability, with a net income of -$29.53 million in Q2 2026 and a gross margin of 27.02%. However, revenue for Q2 2026 was $85.39 million, indicating some resilience in sales despite challenges.